The incidence of nephrogenic systemic fibrosis in subjects receiving gadoversetamide for cardiovascular magnetic resonan
- PDF / 135,247 Bytes
- 2 Pages / 595.28 x 793.7 pts Page_size
- 9 Downloads / 162 Views
POSTER PRESENTATION
Open Access
The incidence of nephrogenic systemic fibrosis in subjects receiving gadoversetamide for cardiovascular magnetic resonance Anna Lisa Crowley*, Han W Kim, Michele Parker, Deneen Spatz, Brenda Hayes, Lubna Bhatti, Christoph J Jensen, Jessica Ngo, John A Papalas, Patrick Pun, John P Middleton, Robert M Judd, Raymond J Kim From 15th Annual SCMR Scientific Sessions Orlando, FL, USA. 2-5 February 2012 Summary The incidence of nephrogenic systemic fibrosis in subjects receiving gadoversetamide for cardiovascular magnetic resonance is low (0.026% overall and 1.274% in those subjects with CKD Stage 5 on hemodialysis). Background Since 2006, the US Food and Drug Administration (FDA) has recommended restricting gadolinium based contrast agents (GBCAs) for magnetic resonance in patients with renal impairment due to an association of GBCA use with nephrogenic systemic fibrosis (NSF). The multiple FDA warnings have listed different glomerular filtration rate (GFR) cut-off values for restricting GBCA use. Consequently, hospital policies vary in renal impairment screening criteria and restrictions for both agent-specific and GFR cut-off values for GBCA use. Determining the incidence of developing NSF after exposure to specific GBCAs, and when stratified by chronic kidney disease (CKD) stage, may clarify which agents and patients are at highest risk for developing NSF. Currently, the incidence of developing NSF after exposure to gadoversetamide (Covidien, Mansfield MA) is unknown. The objective of this study was to determine the incidence and patients at highest risk of developing NSF in a large cohort of patients with suspected cardiovascular disease receiving gadoversetamide. Methods Enrolled adult patients (n=7653) received gadoversetamide for a cardiovascular magnetic resonance (CMR) imaging study at Duke University Medical Center
between July 1, 2002 and July 31, 2008. All database creatinine and gadoversetamide doses were verified by examining the original documentation at the time of the CMR. Multiple, redundant search strategies were performed in parallel to identify subjects with NSF including interrogation of Duke pathology, nephrology, and other available clinical databases. All search strategies were cross-matched against one another to verify that the same patients were identified using each strategy. For patients with CKD Stages 4 (n=263) and 5 (n=174), all available medical records were individually examined with particular attention paid to nephrology, dermatology, rheumatology, and pathology encounters. Incidence of NSF and 95% confidence intervals were determined overall and stratified by CKD stage.
Results Two patients developed NSF. See figure 1. Conclusions The incidence of developing NSF after exposure to gadoversetamide is low (overall: 0.026%; CKD Stage 5 on hemodialysis: 1.274%) in the largest cohort to date examining gadoversetamide. Both NSF patients had CKD Stage 5 on hemodialysis. Zero patients with Stage 5 CKD not on hemodialysis developed NSF. The wide 95% confidenc
Data Loading...
